Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,164.46 USD
+23.01 (2.02%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $1,164.48 +0.02 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Brokerage Reports
Regeneron Pharmaceuticals, Inc. [REGN]
Reports for Purchase
Showing records 81 - 100 ( 595 total )
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for REGN 62122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for REGN 61122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for REGN 6122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Novel Compounds to Treat ATTR Amyloidosis Appear on Track to Generate Peak Annual Revenues of $50B-Plus
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sanofi Immunology Investor Event Highlights Dupixent Successes; COPD Readout in 2023; Making Inroads into China and More
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eylea Rival List Narrows; Wet AMD Contender, KSI-301 Fails in a Phase 2b/3 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dupixent Trial For Omalizumab Refractory CSU Stopped Due to Futility
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Reassuring CANDELA Phase 2 Trial Data Turns Up the Heat in Battle for the Crown in Wet AMD; Reiterate Buy and $843 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M